AR106875A1 - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer - Google Patents

Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Info

Publication number
AR106875A1
AR106875A1 ARP160103664A ARP160103664A AR106875A1 AR 106875 A1 AR106875 A1 AR 106875A1 AR P160103664 A ARP160103664 A AR P160103664A AR P160103664 A ARP160103664 A AR P160103664A AR 106875 A1 AR106875 A1 AR 106875A1
Authority
AR
Argentina
Prior art keywords
tiadiazol
compounds
cancer treatment
compound
formula
Prior art date
Application number
ARP160103664A
Other languages
English (en)
Inventor
Bailey Andrew
Duncan Smith Peter
Antoni Raubo Piotr
Wilhelmus Maria Nissink Johannes
Raymond Verschoyle Finlay Maurice
Robert Perkins David
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of AR106875A1 publication Critical patent/AR106875A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describe un compuesto de la fórmula (1), o una sal del mismo aceptable desde el punto de vista farmacéutico; Q puede ser piridazin-3-ilo, 6-fluoropiridazin 3-ilo; R¹ puede ser H; R² y R³ pueden ser cada uno independientemente alquilo C₁₋₆, o R² y R³ tomados juntos son -(CH₂)₃-; o R¹ y R² tomados juntos pueden ser -(CH₂)₂- y R³ puede ser -CH₃; R⁴ es halo, -CH₃, -OCH₃, -OCHF₂, -OCF₃, o -CN; y n puede ser 0, 1, ó 2. El compuesto de la fórmula (1) puede inhibir la glutaminasa, por ejemplo, GLS1.
ARP160103664A 2015-11-30 2016-11-30 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer AR106875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30

Publications (1)

Publication Number Publication Date
AR106875A1 true AR106875A1 (es) 2018-02-28

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103664A AR106875A1 (es) 2015-11-30 2016-11-30 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Country Status (28)

Country Link
US (1) US10040789B2 (es)
EP (1) EP3383872B1 (es)
JP (1) JP6821680B2 (es)
KR (1) KR20180083411A (es)
CN (1) CN108349965B (es)
AR (1) AR106875A1 (es)
AU (1) AU2016361834B2 (es)
BR (1) BR112018008330B1 (es)
CA (1) CA3005517C (es)
CL (1) CL2018001409A1 (es)
CO (1) CO2018006930A2 (es)
DK (1) DK3383872T3 (es)
DO (1) DOP2018000135A (es)
EA (1) EA035519B9 (es)
ES (1) ES2796562T3 (es)
IL (1) IL259508A (es)
MX (1) MX2018006483A (es)
MY (1) MY195680A (es)
NI (1) NI201800063A (es)
NZ (1) NZ743699A (es)
PE (1) PE20181522A1 (es)
PH (1) PH12018501133A1 (es)
SG (1) SG11201803808VA (es)
SV (1) SV2018005700A (es)
TN (1) TN2018000118A1 (es)
TW (1) TW201731511A (es)
WO (1) WO2017093301A1 (es)
ZA (1) ZA201804361B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
JP7026852B2 (ja) * 2018-10-16 2022-02-28 メッドシャイン ディスカバリー インコーポレイテッド チアジアゾール誘導体及びｇｌｓ１阻害剤としてのその使用
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201692166A1 (ru) 2011-11-21 2017-07-31 Калитера Байосайенсиз Инк. Гетероциклические ингибиторы глютаминазы
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN111393431A (zh) 2014-01-06 2020-07-10 理森制药股份公司 谷氨酰胺酶抑制剂
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
SV2018005700A (es) 2019-03-07
AU2016361834B2 (en) 2019-11-14
DK3383872T3 (da) 2020-06-08
CN108349965B (zh) 2021-10-26
TN2018000118A1 (en) 2019-10-04
DOP2018000135A (es) 2018-06-30
PH12018501133A1 (en) 2019-01-21
CL2018001409A1 (es) 2018-12-07
JP6821680B2 (ja) 2021-01-27
BR112018008330B1 (pt) 2023-03-07
TW201731511A (zh) 2017-09-16
NZ743699A (en) 2023-02-24
CA3005517C (en) 2023-12-12
US20170333429A1 (en) 2017-11-23
EP3383872A1 (en) 2018-10-10
EA035519B9 (ru) 2020-08-10
KR20180083411A (ko) 2018-07-20
SG11201803808VA (en) 2018-06-28
PE20181522A1 (es) 2018-09-24
MX2018006483A (es) 2019-08-12
AU2016361834A1 (en) 2018-07-12
ES2796562T3 (es) 2020-11-27
MY195680A (en) 2023-02-03
ZA201804361B (en) 2019-07-31
EP3383872B1 (en) 2020-05-20
CO2018006930A2 (es) 2018-10-10
CA3005517A1 (en) 2017-06-08
BR112018008330A2 (pt) 2018-10-30
IL259508A (en) 2018-07-31
NI201800063A (es) 2018-10-18
US10040789B2 (en) 2018-08-07
EA201891239A1 (ru) 2018-11-30
WO2017093301A1 (en) 2017-06-08
JP2018535235A (ja) 2018-11-29
CN108349965A (zh) 2018-07-31
EA035519B1 (ru) 2020-06-29

Similar Documents

Publication Publication Date Title
AR106875A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
CL2015000942A1 (es) Compuestos de benceno sustituido.
AR103680A1 (es) Inhibidores selectivos de bace1
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
EA202090860A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
CL2015002897A1 (es) Inhibidores de bace1
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
CL2018001407A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
CL2017001088A1 (es) Regimen de dosificación para interferón pegilado
UY36084A (es) Activadores de herg policíclicos
CO2017007940A2 (es) Péptidos antagonistas prgc

Legal Events

Date Code Title Description
FB Suspension of granting procedure